Immatics' (IMTX) Overweight Rating Reiterated at Cantor Fitzgerald

Immatics (NASDAQ:IMTX - Get Free Report)'s stock had its "overweight" rating reissued by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday,Benzinga reports. Cantor Fitzgerald also issued estimates for Immatics' FY2025 earnings at ($1.53) EPS.

Immatics Price Performance

NASDAQ:IMTX traded down $0.34 during mid-day trading on Tuesday, reaching $3.50. The stock had a trading volume of 1,530,315 shares, compared to its average volume of 637,077. Immatics has a 1-year low of $3.39 and a 1-year high of $13.77. The company has a market capitalization of $417.75 million, a price-to-earnings ratio of -5.30 and a beta of 0.85. The stock's 50 day simple moving average is $4.81 and its two-hundred day simple moving average is $7.20.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.51. The firm had revenue of $15.67 million for the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Sell-side analysts anticipate that Immatics will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC lifted its holdings in shares of Immatics by 34.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after purchasing an additional 2,479 shares during the last quarter. Guggenheim Capital LLC acquired a new position in shares of Immatics in the fourth quarter worth about $101,000. Forefront Analytics LLC grew its position in Immatics by 42.3% during the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after purchasing an additional 4,731 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new position in Immatics during the third quarter valued at $114,000. Institutional investors own 64.41% of the company's stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.